Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple sclerosis

Showing 15 posts of 107 posts found.

celgene_1_02

FDA refuses to review Celgene’s ozanimod in multiple sclerosis

February 28, 2018
Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …

News
biogen_idec_hillerod_2008

Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …

News
roche_close

Roche’s Ocrevus gets the go ahead in Europe for two forms of MS

January 12, 2018
Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …

News

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

News
roche_dark_0

EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis

November 13, 2017
Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

News
nhs_sign

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

News
nerves

Breakthrough study could revolutionise MS treatment

October 13, 2017
Medical Communications, Research and Development biotech, drugs, multiple sclerosis, pharma, pharmaceutical

The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from …

News
roche

Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus

September 28, 2017
Sales and Marketing Ocrevus, Roche, multiple sclerosis, pharma, pharmaceutical

Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing …

News
novartis_side_building

Novartis celebrates success of Gilenya in paediatric multiple sclerosis

September 5, 2017
Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …

News
merck_kgaa_pyramid_use_with_credit

Seven years later, EC gives approval for Merck KGaA’s MS drug

August 25, 2017
Medical Communications, Sales and Marketing Mavenclad, Merck KGaA, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …

News
shutterstock_236161768

Novartis launches first large-scale smartphone-based study in multiple sclerosis

August 23, 2017
Research and Development MS, Novartis, life sciences, multiple sclerosis, pharma, pharmaceuticals

Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis …

News
francesa

US Congressmen accuse Teva of price hikes over 1,000%

August 21, 2017
Sales and Marketing Copaxone, Teva, life sciences, medicine, multiple sclerosis, pharma, pharmaceutical, price hiking

A pair of US Congressmen have fired allegations at Israeli drugmaker Teva accusing the firm of hiking the price of …

News
A example of a myelinated neuron

Old antibiotic offers potential cost-effective MS treatment

June 2, 2017
Medical Communications, Research and Development Myelin, multiple sclerosis

The cost of treatment for multiple sclerosis varies wildly, in the UK treatment can cost £56,000 per year while in …

News
folder

Common treatment for MS revealed to have potential adverse reactions

May 16, 2017
Manufacturing and Production, Research and Development MS, multiple sclerosis

Beta interferons are a common treatment used to manage multiple sclerosis. The treatment works by reducing and preventing the inflammation …

News
pills-384846_960_720

£6 million statin study to determine potential therapeutic use in MS

May 9, 2017
Manufacturing and Production, Research and Development multiple sclerosis, statins

A large study will take place in the UK to determine whether statins, commonly prescribed to combat “bad cholesterol”, are …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026